BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37983866)

  • 21. Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
    Borah NA; Reddy MM
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer.
    Zhang B; Zhu C; Chan ASC; Lu G
    Eur J Med Chem; 2023 Aug; 256():115457. PubMed ID: 37207533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
    Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
    Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a future for Aurora kinase inhibitors for anticancer therapy?
    Carpinelli P; Moll J
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
    Lens SM; Voest EE; Medema RH
    Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors.
    Xie L; Kassner M; Munoz RM; Que QQ; Kiefer J; Zhao Y; Mousses S; Yin HH; Von Hoff DD; Han H
    Biochem Pharmacol; 2012 Feb; 83(4):452-61. PubMed ID: 22100984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.
    Hoellein A; Pickhard A; von Keitz F; Schoeffmann S; Piontek G; Rudelius M; Baumgart A; Wagenpfeil S; Peschel C; Dechow T; Bier H; Keller U
    Oncotarget; 2011 Aug; 2(8):599-609. PubMed ID: 21865609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
    Furqan M; Huma Z; Ashfaq Z; Nasir A; Ullah R; Bilal A; Iqbal M; Khalid MH; Hussain I; Faisal A
    Cell Cycle; 2019 Sep; 18(18):2281-2292. PubMed ID: 31318643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
    Borges KS; Castro-Gamero AM; Moreno DA; da Silva Silveira V; Brassesco MS; de Paula Queiroz RG; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):405-14. PubMed ID: 22160182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).
    Cheung CH; Coumar MS; Chang JY; Hsieh HP
    Expert Opin Ther Pat; 2011 Jun; 21(6):857-84. PubMed ID: 21591849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
    Zhang Q; Shen Q; Gao L; Tong L; Li J; Chen Y; Lu W
    Eur J Med Chem; 2018 Oct; 158():428-441. PubMed ID: 30241010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
    Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
    Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target validation and biomarker identification in oncology : the example of aurora kinases.
    Colombo R; Moll J
    Mol Diagn Ther; 2008; 12(2):71-6. PubMed ID: 18422371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of Aurora-A inhibitors in cancer therapy.
    Agnese V; Bazan V; Fiorentino FP; Fanale D; Badalamenti G; Colucci G; Adamo V; Santini D; Russo A
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi47-52. PubMed ID: 17591831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
    Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
    Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
    Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
    Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.